treatment options

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study

Study Overview The study investigates the efficacy of three therapeutic agents—ripertamab, rituximab, and efgartigimod—in treating chronic inflammatory demyelinating polyneuropathy (CIDP), […]

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study Read Post »

Scroll to Top